Article
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood - 15 Feb 2008
le Coutre Philipp, Ottmann Oliver G, Giles Francis, Kim Dong-Wook, Cortes Jorge, Gattermann Norbert, Apperley Jane F, Larson Richard A, Abruzzese Elisabetta, O'Brien Stephen G, Kuliczkowski Kazimierz, Hochhaus Andreas, Mahon Francois-Xavier, Saglio Giuseppe, Gobbi Marco, Kwong Yok-Lam, Baccarani Michele, Hughes Timothy, Martinelli Giovanni, Radich Jerald P, Zheng Ming, Shou Yaping, Kantarjian Hagop
Abstract excerpt
Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor. This phase 2 trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily) in this patient population with hematologic response (HR) as primary efficacy endpoint. A total of...
Topics
Join the communities discussing this publication.